Summarized by Masters of Longevity from Longevity Technology.
Report on Canada’s drug agency reversing course to recommend public reimbursement for an anti-amyloid Alzheimer’s antibody, outlining access implications and broader sector context.
Key Takeaways
- Canada’s drug agency issued a final recommendation to publicly reimburse lecanemab for eligible patients with mild cognitive impairment or mild Alzheimer’s disease.
- Lecanemab is developed by Eisai with BioArctic and co-commercialized by Biogen, and it already has approval in 53 countries and regions.
- Subcutaneous at-home maintenance dosing and a simplified starting dose were approved to make ongoing treatment easier for patients.
